BTK and systemic lupus erythematosus: Another irreversible BTK inhibitor, BI-BTK-1, ameliorated multiple pathological endpoints associated with kidney disease in two distinct murine models of spontaneous lupus nephritis in mouse models of SLE: NZB × NZW F1 (NZB/W) and MRL/lpr [111].